Bones and Crohn's: No benefit of adding sodium fluoride or ibandronate to calcium and vitamin D

World Journal of Gastroenterology

Volumn 17, Issue 3, 2011, Pages 334-342

  Klaus, Jochen ^a   Reinshagen, Max ^b   Herdt, Katharina ^a   Schröter, Christoph ^a   Adler, Guido ^a   von Boyen, Georg B T ^a   von Tirpitz, Christian ^c  

^a UNIVERSITY OF ULM   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

^c Medizinische Klinik   (Germany)

Author keywords

Bone mineral density; Calcium; Cholecalciferol; Crohn's disease; Ibandronate; Sodium fluoride; Vertebral fracture

Indexed keywords

CALCITRAT; CITRATE CALCIUM; COLECALCIFEROL; FLUORIDE SODIUM; IBANDRONIC ACID; NAFRIL; UNCLASSIFIED DRUG; VIGANTOLETTEN; VITAMIN D;

ADD ON THERAPY; ADULT; ARTICLE; BONE DENSITY; BONE PAIN; CONTROLLED STUDY; CROHN DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SPINE RADIOGRAPHY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 79955777591     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i3.334     Document Type: Article

References (48)

1. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J. Osteoporosis in patients with infammatory bowel disease. Gut 1987; 28: 410-415
2. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B. Metabolic bone assessment in patients with infammatory bowel disease. Gastroen-terology 1995; 108: 417-422
3. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with infammatory bowel disease. Gut 1997; 40: 228-233
4. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 313-319
5. Silvennoinen JA, Karttunen TJ, Niemelä SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with infammatory bowel disease. Gut 1995; 37: 71-76
6. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in infammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10: 250-256
7. Von Tirpitz C, Pischulti G, Klaus J, Rieber A, Brückel J, Böhm BO, Adler G, Reinshagen M. [Pathological bone density in chronic infammatory bowel diseases--prevalence and risk factors]. Z Gastroenterol 1999; 37: 5-12
8. von Tirpitz C, Epp S, Klaus J, Mason R, Hawa G, Brinskelle-Schmal N, Hofbauer LC, Adler G, Kratzer W, Reinshagen M. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2003; 15: 1165-1170
9. Schulte CM, Dignass AU, Goebell H, Röher HD, Schulte KM. Genetic factors determine extent of bone loss in infam-matory bowel disease. Gastroenterology 2000; 119: 909-920
10. Todhunter CE, Sutherland-Craggs A, Bartram SA, Donaldson PT, Daly AK, Francis RM, Mansfeld JC, Thompson NP. Infuence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease. Gut 2005; 54: 1579-1584
11. Bartram SA, Peaston RT, Rawlings DJ, Walshaw D, Francis RM, Thompson NP. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J Gastroenterol 2006; 12: 5680-5686
12. Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, infam-mation and osteoporosis: basic and clinical concepts. Gut 2008; 57: 684-694
13. Leslie WD, Miller N, Rogala L, Bernstein CN. Vitamin D status and bone density in recently diagnosed infammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastro-enterol 2008; 103: 1451-1459
14. Deutsche Morbus-Crohn-/Colitis-ulcerosa-Vereinigung (DCCV e.V.) [online]. Accessed August 2010. Available from: URL: http://www.dccv.de/
15. Klaus J, Armbrecht G, Steinkamp M, Brückel J, Rieber A, Adler G, Reinshagen M, Felsenberg D, von Tirpitz C. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002; 51: 654-658
16. van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Infammatory bowel disease and the risk of fracture. Gastroenterology 2003; 125: 1591-1597
17. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with infammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 795-799
18. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46: 176-181
19. le Pen C, Maurel F, Breart G, Lopes P, Plouin PF, Allicar MP, Roux C. The long-term effectiveness of preventive strategies for osteoporosis in postmenopausal women: a modeling approach. Osteoporos Int 2000; 11: 524-532
20. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-1443
21. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382-387
22. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-1541
23. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meuni-er PJ, Reginster JY. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-340
24. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkes-tad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schim-mer RC, Delmas PD. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249
25. Kanis JA, Borgstrom F, Johnell O, Jonsson B. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004; 15: 862-871
26. Johnell O, Jönsson B, Jönsson L, Black D. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21: 305-314
27. Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fuoride. Final report of a randomized controlled trial. Ann Intern Med 1995; 123: 401-408
28. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ 3rd. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-809
29. Rubin CD, Pak CY, Adams-Huet B, Genant HK, Li J, Rao DS. Sustained-release sodium fuoride in the treatment of the elderly with established osteoporosis. Arch Intern Med 2001; 161: 2325-2333
30. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroen-terol Hepatol 1995; 7: 609-614
31. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with in-fammatory bowel disease. Gut 1993; 34: 1543-1546
32. von Tirpitz C, Klaus J, Brückel J, Rieber A, Scholer A, Adler G, Böhm BO, Reinshagen M. Increase of bone mineral density with sodium fuoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000; 12: 19-24
33. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1121-1127
34. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendro-nate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119: 639-646
35. Siffedeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2005; 3: 122-132
36. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129
37. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444
38. McCloskey EV, Spector TD, Eyres KS, Fern ED, O'Rourke N, Vasikaran S, Kanis JA. The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 1993; 3: 138-147
39. Black DM, Palermo L, Nevitt MC, Genant HK, Christensen L, Cummings SR. Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999; 14: 90-101
40. Felsenberg D, Wieland E, Gowin W, Armbrecht G, Bolze X, Khorassani A, Weingarten U. [Morphometric analysis of roentgen images of the spine for diagnosis of osteoporosis-induced fracture]. Med Klin (Munich) 1998; 93 Suppl 2: 26-30
41. Felsenberg D, Armbrecht G, Khorassani A. Europäische Prospektive Osteoporosestudie (EPOS). Förderungsprojekt des Bundesministeriums für Bildung, Wissenschaft, Forsc-hung und Technologie (BMBF). Förderkennzeichen 01 KM 9402/3. Berlin: German Ministry of Research, 1996
42. Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 1996; 11: 587-593
43. Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103: 298-307
44. Sebba AI, Emkey RD, Kohles JD, Sambrook PN. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 2009; 44: 423-427
45. von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R, Boehm BO, Adler G, Reinshagen M. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fuoride and ibandronate. Aliment Pharmacol Ther 2003; 17: 807-816
46. Pak CY, Sakhaee K, Parcel C, Poindexter J, Adams B, Bahar A, Beckley R. Fluoride bioavailability from slow-release sodium fuoride given with calcium citrate. J Bone Miner Res 1990; 5: 857-862
47. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 795-841
48. Kornbluth A, Hayes M, Feldman S, Hunt M, Fried-Boxt E, Lichtiger S, Legnani P, George J, Young J. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. Am J Gastroenterol 2006; 101: 1546-1550